275 related articles for article (PubMed ID: 36612255)
1. Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors.
Pandya PH; Jannu AJ; Bijangi-Vishehsaraei K; Dobrota E; Bailey BJ; Barghi F; Shannon HE; Riyahi N; Damayanti NP; Young C; Malko R; Justice R; Albright E; Sandusky GE; Wurtz LD; Collier CD; Marshall MS; Gallagher RI; Wulfkuhle JD; Petricoin EF; Coy K; Trowbridge M; Sinn AL; Renbarger JL; Ferguson MJ; Huang K; Zhang J; Saadatzadeh MR; Pollok KE
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612255
[TBL] [Abstract][Full Text] [Related]
2. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of patient-derived xenografts from patients with osteosarcoma.
Chen F; Zhang Z; Shen R; Chen M; Li G; Zhu X
Tissue Cell; 2022 Dec; 79():101911. PubMed ID: 36156374
[TBL] [Abstract][Full Text] [Related]
4. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis.
Wang J; Xing B; Liu W; Li J; Wang X; Li J; Yang J; Ji C; Li Z; Dong B; Gao J; Shen L
Theranostics; 2019; 9(12):3485-3500. PubMed ID: 31281492
[No Abstract] [Full Text] [Related]
5. Precision Medicine Highlights Dysregulation of the CDK4/6 Cell Cycle Regulatory Pathway in Pediatric, Adolescents and Young Adult Sarcomas.
Barghi F; Shannon HE; Saadatzadeh MR; Bailey BJ; Riyahi N; Bijangi-Vishehsaraei K; Just M; Ferguson MJ; Pandya PH; Pollok KE
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892870
[TBL] [Abstract][Full Text] [Related]
6. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.
Drapkin BJ; George J; Christensen CL; Mino-Kenudson M; Dries R; Sundaresan T; Phat S; Myers DT; Zhong J; Igo P; Hazar-Rethinam MH; Licausi JA; Gomez-Caraballo M; Kem M; Jani KN; Azimi R; Abedpour N; Menon R; Lakis S; Heist RS; Büttner R; Haas S; Sequist LV; Shaw AT; Wong KK; Hata AN; Toner M; Maheswaran S; Haber DA; Peifer M; Dyson N; Thomas RK; Farago AF
Cancer Discov; 2018 May; 8(5):600-615. PubMed ID: 29483136
[TBL] [Abstract][Full Text] [Related]
7. Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts.
Moy RH; Walch HS; Mattar M; Chatila WK; Molena D; Strong VE; Tang LH; Maron SB; Coit DG; Jones DR; Hechtman JF; Solit DB; Schultz N; de Stanchina E; Janjigian YY
JCO Precis Oncol; 2022 Feb; 6():e2100242. PubMed ID: 35138918
[TBL] [Abstract][Full Text] [Related]
8. Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
Lang H; Béraud C; Cabel L; Fontugne J; Lassalle M; Krucker C; Dufour F; Groeneveld CS; Dixon V; Meng X; Kamoun A; Chapeaublanc E; De Reynies A; Gamé X; Rischmann P; Bieche I; Masliah-Planchon J; Beaurepere R; Allory Y; Lindner V; Misseri Y; Radvanyi F; Lluel P; Bernard-Pierrot I; Massfelder T
Front Oncol; 2022; 12():930731. PubMed ID: 36033544
[TBL] [Abstract][Full Text] [Related]
9. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
Pan CX; Zhang H; Tepper CG; Lin TY; Davis RR; Keck J; Ghosh PM; Gill P; Airhart S; Bult C; Gandara DR; Liu E; de Vere White RW
PLoS One; 2015; 10(8):e0134346. PubMed ID: 26270481
[TBL] [Abstract][Full Text] [Related]
10. Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma.
Landuzzi L; Manara MC; Lollini PL; Scotlandi K
Cells; 2021 Feb; 10(2):. PubMed ID: 33671173
[TBL] [Abstract][Full Text] [Related]
11. Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.
Sun B; Wang Y; Sun J; Zhang C; Xia R; Xu S; Sun S; Li J
Am J Cancer Res; 2021; 11(3):773-792. PubMed ID: 33791153
[TBL] [Abstract][Full Text] [Related]
12. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
Palanisamy N; Yang J; Shepherd PDA; Li-Ning-Tapia EM; Labanca E; Manyam GC; Ravoori MK; Kundra V; Araujo JC; Efstathiou E; Pisters LL; Wan X; Wang X; Vazquez ES; Aparicio AM; Carskadon SL; Tomlins SA; Kunju LP; Chinnaiyan AM; Broom BM; Logothetis CJ; Troncoso P; Navone NM
Clin Cancer Res; 2020 Sep; 26(18):4933-4946. PubMed ID: 32576626
[TBL] [Abstract][Full Text] [Related]
13. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
[TBL] [Abstract][Full Text] [Related]
14. Genomic and Molecular Signatures of Successful Patient-Derived Xenografts for Oral Cavity Squamous Cell Carcinoma.
Yen WC; Chang IY; Chang KP; Ouyang CN; Liu CR; Tsai TL; Zhang YC; Wang CI; Wang YH; Yu AL; Liu H; Wu CC; Chang YS; Yu JS; Yang CY
Front Oncol; 2022; 12():792297. PubMed ID: 35444950
[TBL] [Abstract][Full Text] [Related]
15. Xenografts derived from patients with head and neck cancer recapitulate patient tumour properties.
Makita H; Endo K; Kasahara Y; Nakata A; Moriyama-Kita M; Ishikawa K; Ueno T; Nakanishi Y; Kondo S; Wakisaka N; Gotoh N; Yoshizaki T
Oncol Lett; 2021 May; 21(5):385. PubMed ID: 33777208
[TBL] [Abstract][Full Text] [Related]
16. Disparity in Outcomes for Adolescent and Young Adult Patients Diagnosed With Pediatric Solid Tumors Across 4 Decades.
Chen I; Pasalic D; Fischer-Valuck B; Frangoul H; DeWees T; Shinohara ET; Perkins SM
Am J Clin Oncol; 2018 May; 41(5):471-475. PubMed ID: 27841802
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
18. Establishment of 6 pediatric rhabdomyosarcoma patient's derived xenograft models closely recapitulating patients' tumor characteristics.
Gasparini P; Casanova M; Centonze G; Borzi C; Bergamaschi L; Collini P; Testi A; Chiaravalli S; Massimino M; Sozzi G; Ferrari A; Moro M
Tumori; 2023 Jun; 109(3):314-323. PubMed ID: 36114629
[TBL] [Abstract][Full Text] [Related]
19. DNA-based copy number analysis confirms genomic evolution of PDX models.
Hoge ACH; Getz M; Zimmer A; Ko M; Raz L; Beroukhim R; Golub TR; Ha G; Ben-David U
NPJ Precis Oncol; 2022 Apr; 6(1):30. PubMed ID: 35484194
[TBL] [Abstract][Full Text] [Related]
20. Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs.
Punzi S; Meliksetian M; Riva L; Marocchi F; Pruneri G; Criscitiello C; Orsi F; Spaggiari L; Casiraghi M; Della Vigna P; Luzi L; Curigliano G; Pelicci PG; Lanfrancone L
Cells; 2019 Jun; 8(6):. PubMed ID: 31216647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
